Anti-CLL-1 antibodies and methods of use
RF Kelley, SR Leong, WC Liang, M Mathieu… - US Patent …, 2019 - Google Patents
US10501545B2 - Anti-CLL-1 antibodies and methods of use - Google Patents
US10501545B2 - Anti-CLL-1 antibodies and methods of use - Google Patents Anti-CLL-1 …
US10501545B2 - Anti-CLL-1 antibodies and methods of use - Google Patents Anti-CLL-1 …
Anti-CD3 antibodies and methods of use
X Chen, MS Dennis, AJ Ebens Jr, TT Junttila… - US Patent …, 2020 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
52394341&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
52394341&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
B Elliott, T Ahmadi, WL Christopher… - US Patent 11,535,679, 2022 - Google Patents
2020/0199231 A1 6/2020 Engelberts et al. 2020/0262932 Al 8/2020 Labrijn et al.
2020/0332022 Al 10/2020 Labrijn et al. 2021/0371538 A1* 12/2021 Ahmadi CO7K 16/2887 …
2020/0332022 Al 10/2020 Labrijn et al. 2021/0371538 A1* 12/2021 Ahmadi CO7K 16/2887 …
Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
B Elliott, T Ahmadi, WL Christopher, ECW Breij… - US Patent …, 2023 - Google Patents
2022-03-08 Assigned to GENMAB A/S reassignment GENMAB A/S ASSIGNMENT OF
ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BREIJ, Esther CW …
ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BREIJ, Esther CW …
Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma
B Elliott, T Ahmadi - US Patent 11,548,952, 2023 - Google Patents
2020/0199231 A1 6/2020 Engelberts et al. 2020/0262932 Al 8/2020 Labrijn et al.
2020/0332022 Al 10/2020 Labrijn et al. 2021/0371538 A1* 12/2021 Ahmadi CO7K 16/2887 …
2020/0332022 Al 10/2020 Labrijn et al. 2021/0371538 A1* 12/2021 Ahmadi CO7K 16/2887 …
Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
CC Li, CE O'HEAR, H Wang, BC BENDER… - US Patent App. 17 …, 2022 - Google Patents
2022-07-21 Assigned to GENENTECH, INC. reassignment GENENTECH, INC.
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors …
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors …
Bispecific antigen-binding molecules and methods of use
D Ellerman, TT Junttila, TN Lombana, D Slaga… - US Patent …, 2024 - Google Patents
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-
amino-3-phenylpropanoyl] amino]-3-phenylpropanoyl] amino]-4-methylpentanoyl] amino] …
amino-3-phenylpropanoyl] amino]-3-phenylpropanoyl] amino]-4-methylpentanoyl] amino] …
Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
CE O'hear, Y Oki - US Patent App. 17/744,262, 2022 - Google Patents
US20220411528A1 - Methods for treatment of cd20-positive proliferative disorder with
mosunetuzumab and polatuzumab vedotin - Google Patents US20220411528A1 - Methods …
mosunetuzumab and polatuzumab vedotin - Google Patents US20220411528A1 - Methods …
Pharmaceutical compositions of mosunetuzumab and methods of use
JA Ji, JY Tyler - US Patent 11,958,906, 2024 - Google Patents
BACKGROUND Mosunetuzumab is being increasingly used as treatments for cancers, eg,
CD20-positive cell proliferative disorders (eg, B cell proliferative disorders, eg, non …
CD20-positive cell proliferative disorders (eg, B cell proliferative disorders, eg, non …